365
Views
0
CrossRef citations to date
0
Altmetric
Articles

Management of hypertension in patients with type 2 diabetes mellitus

, BSc(Med), MBChB, MMed(Int), HDip(Int)(SA), FCP(SA)
Pages 41-44 | Received 09 Jun 2012, Accepted 14 Jan 2013, Published online: 15 Aug 2014

References

  • Chobanian AV, Bakris AJ, Black HR, et al. The seventh report of the joint National Committee on Prevention, Detection, Evaluation and treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003; 289(19): 2560–2572.
  • Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998; 317(7160): 703–713.
  • Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 DM: UKPD 40. UK Prospective Diabetes Study Group. BMJ. 1998; 317(7160): 720–726.
  • Society for Endocrinology, Metabolism and Diabetes of South Africa. The 2012 SEMDSA guidelines for the management of type 2 diabetes. JEMDSA. 2012; 17(2) (Supplement 1): S1–S95.
  • Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ. 1998; 317(7160): 713–720.
  • American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care. 2003; 26: 80–82.
  • Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE Study and MICRO-HOPE sub-study. Lancet. 2000; 355(9200): 253–259.
  • National Kidney Foundation KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic didney disease, guideline 3: management of hypertension in diabetes and chronic kidney disease. National Kidney Foundation [homepage on the Internet]. Available from: www.kidney.org/professionals/kdoqi/guideline_diabetes/guide3.htm
  • Marco P, Lonneke VF, Steven RD, et al. Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1. Circulation. 2002; 105(4): 457–461.
  • Carlos AP Marian AP, Phillip R. The treatment of hypertension in adult patients with diabetes. Diabetes Care. 2002, 25; 134–147.
  • The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, The Antihypertensive and Lipid-lowering Treatment to prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients Randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic; the Antihypertensive and Lipid-lowering Treatment to prevent Heart Attack Trial (ALLHAT) JAMA. 2002; 288(23); 2981–2997.
  • PROGRESS Collaborative Group. Randomized trial of a perindopril-based blood pressure-lowering regimen among 6105 individuals with stroke or transient ischemic attack. Lancet. 2001; 358(9287): 1033–1041.
  • Opie LH, Schall R. Old antihypertensives and new diabetes. J Hypertens. 2004; 22(8): 1453–1458.
  • Mason J, Dickinson H, Nicolson D, et al. The diabetogenic potential of thiazide diuretics and beta blocker combination in the management of hypertension. J Hypertens. 2005; 23(10): 1777–1781.
  • Alvin CP. Diabetes mellitus. In: Longo DL, Fauci AS, Kasper DL, editors. Harrison's principles of internal medicine. 18th ed. New York: McGraw-Hill, 2012; p. 2968–3003.
  • Raymond O, Estacio MD, Barrett W, et al. The effects of nisoldipine as compared with enalapril on cardiovascular outcomes in patient with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998; 338(10): 645–652.
  • Comparison between perindopril and nifedipine in hypertension and normotensive diabetic patients with microalbuminuria. Melbourne Diabetic Nephropathy Study Group. BMJ. 1991; 302(6770): 210–216.
  • Anne PH, Ruchi M. Complications of diabetes mellitus: primary care implications. In: Christine AB, William H, Francine RK, editors. Davidson's diabetes mellitus: diagnosis and treatment. 5th ed. United States: Saunders, 2004; p. 189–238.